Maria Koehler

Pediatrics

19 Shirley Rd
Narberth, PA 19072

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.

Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.

Journal: The New England journal of medicine

Published: January 28, 2026

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 01, 2021

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.

Journal: The Lancet. Oncology

Published: September 02, 2020

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 08, 2018

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.

Journal: Nature communications

Published: July 19, 2017

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 19, 2016

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 09, 2016

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

Journal: The Lancet. Oncology

Published: October 16, 2015

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Journal: The New England journal of medicine

Published: June 02, 2015

Showing 1-9 of 9

Last Updated: 09/26/2026